Cargando…
Differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations
OBJECTIVES: Pertussis toxin (PT) is a component of all acellular pertussis vaccines. PT must be detoxified to be included in acellular vaccines, which results in conformational changes in the functional epitopes of PTs. Therefore, induced epitope‐specific antibodies to PT may vary after vaccinations...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396262/ https://www.ncbi.nlm.nih.gov/pubmed/32765879 http://dx.doi.org/10.1002/cti2.1161 |
_version_ | 1783565553044029440 |
---|---|
author | Knuutila, Aapo Dalby, Tine Barkoff, Alex‐Mikael Jørgensen, Charlotte Sværke Fuursted, Kurt Mertsola, Jussi Markey, Kevin He, Qiushui |
author_facet | Knuutila, Aapo Dalby, Tine Barkoff, Alex‐Mikael Jørgensen, Charlotte Sværke Fuursted, Kurt Mertsola, Jussi Markey, Kevin He, Qiushui |
author_sort | Knuutila, Aapo |
collection | PubMed |
description | OBJECTIVES: Pertussis toxin (PT) is a component of all acellular pertussis vaccines. PT must be detoxified to be included in acellular vaccines, which results in conformational changes in the functional epitopes of PTs. Therefore, induced epitope‐specific antibodies to PT may vary after vaccinations or natural infections, and this information could reveal biomarkers implicated for protection and successful immunisation. METHODS: Pertussis toxin epitope‐specific antibodies in sera from 152 vaccinated children and 72 serologically confirmed patients were tested with a blocking ELISA, based on monoclonal antibodies that target protective PT epitopes. RESULTS: All study groups induced considerable antibody titres to subunit 1 (S1). Of interest, S3 7E10‐specific antibodies were present in patients, but not after vaccinations (P < 0.001). The impact of glutaraldehyde treatment of PT was visible on epitope 1D7 (S1), whereas epitopes 1B7 (S1) and 10D (S1) were more preserved. Antibodies to these epitopes were higher after three primary vaccine doses than after a single booster dose. CONCLUSION: The high amount of 7E10‐specific antibodies in patients suggests this epitope might be functionally relevant in protection. The overall characteristics of epitope‐specific antibodies are influenced by infection or vaccination background, by the used detoxification method of PT and by the amount of the toxin used in immunisation. |
format | Online Article Text |
id | pubmed-7396262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73962622020-08-05 Differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations Knuutila, Aapo Dalby, Tine Barkoff, Alex‐Mikael Jørgensen, Charlotte Sværke Fuursted, Kurt Mertsola, Jussi Markey, Kevin He, Qiushui Clin Transl Immunology Original Article OBJECTIVES: Pertussis toxin (PT) is a component of all acellular pertussis vaccines. PT must be detoxified to be included in acellular vaccines, which results in conformational changes in the functional epitopes of PTs. Therefore, induced epitope‐specific antibodies to PT may vary after vaccinations or natural infections, and this information could reveal biomarkers implicated for protection and successful immunisation. METHODS: Pertussis toxin epitope‐specific antibodies in sera from 152 vaccinated children and 72 serologically confirmed patients were tested with a blocking ELISA, based on monoclonal antibodies that target protective PT epitopes. RESULTS: All study groups induced considerable antibody titres to subunit 1 (S1). Of interest, S3 7E10‐specific antibodies were present in patients, but not after vaccinations (P < 0.001). The impact of glutaraldehyde treatment of PT was visible on epitope 1D7 (S1), whereas epitopes 1B7 (S1) and 10D (S1) were more preserved. Antibodies to these epitopes were higher after three primary vaccine doses than after a single booster dose. CONCLUSION: The high amount of 7E10‐specific antibodies in patients suggests this epitope might be functionally relevant in protection. The overall characteristics of epitope‐specific antibodies are influenced by infection or vaccination background, by the used detoxification method of PT and by the amount of the toxin used in immunisation. John Wiley and Sons Inc. 2020-08-02 /pmc/articles/PMC7396262/ /pubmed/32765879 http://dx.doi.org/10.1002/cti2.1161 Text en © 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Article Knuutila, Aapo Dalby, Tine Barkoff, Alex‐Mikael Jørgensen, Charlotte Sværke Fuursted, Kurt Mertsola, Jussi Markey, Kevin He, Qiushui Differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations |
title | Differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations |
title_full | Differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations |
title_fullStr | Differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations |
title_full_unstemmed | Differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations |
title_short | Differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations |
title_sort | differences in epitope‐specific antibodies to pertussis toxin after infection and acellular vaccinations |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396262/ https://www.ncbi.nlm.nih.gov/pubmed/32765879 http://dx.doi.org/10.1002/cti2.1161 |
work_keys_str_mv | AT knuutilaaapo differencesinepitopespecificantibodiestopertussistoxinafterinfectionandacellularvaccinations AT dalbytine differencesinepitopespecificantibodiestopertussistoxinafterinfectionandacellularvaccinations AT barkoffalexmikael differencesinepitopespecificantibodiestopertussistoxinafterinfectionandacellularvaccinations AT jørgensencharlottesværke differencesinepitopespecificantibodiestopertussistoxinafterinfectionandacellularvaccinations AT fuurstedkurt differencesinepitopespecificantibodiestopertussistoxinafterinfectionandacellularvaccinations AT mertsolajussi differencesinepitopespecificantibodiestopertussistoxinafterinfectionandacellularvaccinations AT markeykevin differencesinepitopespecificantibodiestopertussistoxinafterinfectionandacellularvaccinations AT heqiushui differencesinepitopespecificantibodiestopertussistoxinafterinfectionandacellularvaccinations |